# Allergy Therapeutics publishes encouraging new data for peanut allergy vaccine candidate

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-publishes-encouraging-new-data-for-peanut-allergy-vaccine-candidate/412804470
- Published: 2020-01-29T13:38:40+00:00
- Author: Amilia Stone

**Allergy Therapeutics** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical company specialising in allergy vaccines,
today announced publication of positive preclinical results of its peanut allergy
vaccine candidate in _The Journal of Allergy and Clinical Immunology (JACI)_.

The study, which introduces the principles of vaccination into the allergy field,
used a peanut allergy mouse model to demonstrate that the novel virus like particle(
VLP) platform used in the vaccine candidate could offer an effective way to treat
peanut allergies and prevent anaphylaxis. It provides the proof of concept for the
generation of sustained immunity and protection through vaccination. The study illustrated
that a single injection protected against systemic anaphylaxis, as demonstrated 
via subsequent _in vivo_ challenge, skin prick testing and oral challenge.

There are currently no approved immunotherapies for the treatment of, or to cure,
patients suffering from peanut allergy, which remains a frequent cause of anaphylactic
reactions among food allergies. Prevalence of peanut allergy in Western countries
ranges from 1.4-3% of children^(1), with UK figures estimating around 2% of children
in the UK are affected^(2). In the US, peanut allergy affects an estimated 1.2% 
of the overall US population^(3) and 1 in 4 children with a peanut allergy require
a hospital visit each year^(4).

In this study mice were immunised with one of three vaccines containing either a
mixture of allergens found in whole extract of roasted peanut or with just one single,
purified peanut allergen (“Ara h 1” or “Ara h 2”). Regardless of which vaccine was
used, immunisation strongly reduced systemic and local allergic symptoms in vaccinated
subjects and protected against anaphylaxis upon subsequent challenge with a whole
peanut allergen mixture. The fact that one injection against a single allergen was
sufficient to induce protection against a whole peanut allergen mixture has never
been described before and is described in the _JACI_ paper as “striking and could
be applied in different relevant allergies”. In addition, the vaccine proved to 
be hypo-allergenic as previously described^(5), which in peanut allergy is a vital
characteristic to avoid anaphylactic reactions upon dosing and to increase compliance.

Allergy Therapeutics’ wholly-owned, subcutaneous, recombinant vaccine candidate,
uses a formulation incorporating novel VLP-based technology, which enhances the 
body’s immune response by making the peanut allergen resemble an invading virus.
The engineered, plant-based cucumber mosaic virus (CuMV) used in the vaccine is 
not able to replicate or to infect humans and so provides a platform to induce protective
antibodies in a way more akin to traditional vaccination rather than current allergen-
specific immunotherapy approaches such as desensitisation via transdermal patches
or oral administration.

> **Professor Martin F. Bachmann, study investigator from The University of Bern,
> Switzerland and The Jenner Institute, University of Oxford, UK, said:** “The impact
> of peanut allergy on patients, their families and health systems is significant
> with prevalence on the rise. While work to develop peanut allergy immunotherapies
> has been the focus of researchers’ attention for some time, these potential immunotherapies
> often require repeated and long-lasting exposure transdermally or orally, which
> can limit patient adherence and have been associated with dangerous systemic allergic
> reactions. The availability of a safe and effective short-course vaccine that 
> provides long-term protection and induces a long-lasting protective immune response
> remains the ultimate goal for researchers in this field. This study indicates 
> a paradigm shift by addressing peanut allergy via a vaccination concept instead
> of classic desensitisation and provides a strong proof of concept for such a vaccine.
> The important next step will be to confirm the effects seen here in patient trials.”

With manufacturing scale up of the product now underway and following agreement 
with several regulatory authorities on the clinical trial design a first-in-human
phase I clinical trial of the candidate vaccine is due to begin.

The scientific publication in JACI, the most frequently cited allergy and immunology
journal in the field, is titled _Vaccine against peanut allergy based on engineered
Virus-Like-Particles displaying single major peanut allergens_ and is available 
online at [www.jacionline.org](http://www.jacionline.org/)  

**References**

_1.   Nwaru BI, Hickstein L, Panesar SS, Muraro A, Werfel T, Cardona V, et al. The
epidemiology of food allergy in Europe: a systematic review and meta-analysis. Allergy.
2014. 1;69(1):62-75. Available from: [http://doi.wiley.com/10.1111/all.12305](http://doi.wiley.com/10.1111/all.12305)_

_2.   Allergy UK, Peanut Allergy Factsheet, [https://www.allergyuk.org/information-and-advice/conditions-and-symptoms/778-peanut-allergy](https://www.allergyuk.org/information-and-advice/conditions-and-symptoms/778-peanut-allergy)_

3.   [https://www.ajmc.com/journals/supplement/2018/managed-care-perspective-peanut-allergy/the-economic-impact-of-peanut-allergies](https://www.ajmc.com/journals/supplement/2018/managed-care-perspective-peanut-allergy/the-economic-impact-of-peanut-allergies)

_4.   Gupta RS, Warren CM, Smith BM, et al. The Public Health Impact of Parent-Reported
Childhood Food Allergies in the United States. Pediatrics. 2018;142(6):e20181235.
Available from: [https://www.ncbi.nlm.nih.gov/pubmed/30455345](https://www.ncbi.nlm.nih.gov/pubmed/30455345)_

_5.   Engeroff P, Caviezel F, Storni F, Thoms F, Vogel M, Bachmann MF. Allergens
displayed on virus-like particles are highly immunogenic but fail to activate human
mast cells. Allergy. 2017;00:1-9. [https://doi.org/10.1111/all.13268](https://doi.org/10.1111/all.13268)_

> **Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: **“
> The development of an effective and safe peanut allergy vaccine would be significant,
> offering huge and life-changing benefits to sufferers affected by this condition.
> The science behind allergy vaccination is incredibly difficult given the complexity
> of our immune systems and at Allergy Therapeutics we have been working on our 
> peanut allergy vaccine for over three years. The results from this study are very
> promising and we’re excited to be progressing the vaccine into its first clinical
> trial in patients this summer.”

Share on:
